-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Reiterates Buy on Annovis Bio, Lowers Price Target to $3

Benzinga·11/16/2026 14:30:19
Listen to the news
Roth Capital analyst Boobalan Pachaiyappan reiterates Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $7 to $3.